



Press Release Aug. 10, 2022

## **Genovis enters licensing and supply agreement with new bioprocess customer**

**Genovis has signed a long-term licensing and supply agreement with a US based biotech company for the supply of SmartEnzymes™ to be used in the manufacturing of a clinical therapeutic agent. The new customer represents Genovis' second partner in the Bioprocess application area.**

The new partner will initially use the Genovis enzyme for the preclinical process development and up-scaling of the manufacturing process to support regulatory submission to enable further clinical development. The initial preclinical development activities are expected to be performed during the first 12-months and generate approximately four million SEK in revenues. The agreement reflects the project spanning from preclinical process development through clinical development and commercial manufacturing. The ultimate goal is to generate a platform of novel therapeutic molecules to bring a series of new treatments to patients with high unmet needs.

“ We are proud to announce a second customer using our SmartEnzymes in bioprocess manufacturing to generate a novel type of biologics. This long-term agreement is a statement of the trust in Genovis as a high-quality supplier of key materials for clinical manufacturing. The agreement further strengthens our strategy to bring new tools and technologies to the biopharma market to meet the growing needs in a broad range of applications, including research, development and manufacturing,” comments Fredrik Olsson, CEO at Genovis.

**For more information**, please contact:

Fredrik Olsson, CEO, Genovis AB,  
Telephone: +46 (0)70 276 46 56  
Email: [fredrik.olsson@genovis.com](mailto:fredrik.olsson@genovis.com)

**Genovis'** business concept is to apply its knowledge and customer driven innovation to design and provide tools for the development of the drugs of the future. Today Genovis sells several enzyme products known as SmartEnzymes™ all over the world in innovative product formats that facilitate development and quality control of biological drugs. The Group consists of Genovis AB and the wholly owned subsidiary Genovis Inc. (US). Genovis shares are listed on Nasdaq First North Growth Market and Erik Penser Bank is the Company's Certified Adviser, [certifiedadviser@penser.se](mailto:certifiedadviser@penser.se), tel: +46 (0)8-463 83 00.